Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Stockholders to Learn More About the Investigation ...

Keros Therapeutics, Inc. (KROS) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates ...

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Investors to Reach Out ...

Group 1 - The article discusses an active investigation regarding Keros Therapeutics, Inc. for investors who may have lost money on their investments [1] Group 2 - Investors are encouraged to contact Levi & Korsinsky for assistance related to their losses in Keros Therapeutics, Inc. [1]

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Stockholders to Reach Out ...

Keros Therapeutics, Inc. (KROS) has been on a downward spiral lately with significant selling pressure. After declining 39.2% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whet ...

Levi & Korsinsky Reminds Keros Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - KROS ...

LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it has voluntarily halted all dosing in the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012 ...

Core Viewpoint - Keros Therapeutics has voluntarily halted dosing in certain treatment arms of the TROPOS trial due to safety concerns related to adverse events observed in patients with pulmonary arterial hypertension [1][2] Group 1: Company Actions - The company announced a halt in dosing for the 3.0 mg/kg and 4.5 mg/kg treatment arms of the TROPOS trial while continuing with the 1.5 mg/kg arm after a safety review [1][2] - Keros is collaborating with the FDA and other regulatory authorities to address the safety concerns and has notified investigators about the decision [2] - The company expects to present topline data from all treatment arms in the TROPOS trial in the second quarter of 2025 [2] Group 2: Trial Information - The TROPOS trial is a Phase 2 clinical trial evaluating the efficacy of cibotercept in patients with pulmonary arterial hypertension [4] - The primary objective of the trial is to assess the effect of cibotercept on pulmonary hemodynamics compared to placebo [4] - The trial is fully enrolled, and the independent Data Monitoring Committee conducted a risk and benefit assessment prior to the dosing halt [2] Group 3: Product Information - Cibotercept is designed to inhibit TGF-β signaling, which is linked to smooth muscle hypertrophy and fibrosis, potentially treating conditions like pulmonary arterial hypertension [5] - The drug aims to enhance BMP signaling pathways, which are often reduced in patients with certain cardiovascular disorders [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ ________________________________________ ________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3 ...